Latest Medicine stories from Life.
Erasca has reported that its experimental treatment for pancreatic and lung cancers has delivered results that exceed initial expectations in early trials.
The Trump administration has expressed concerns regarding the use of federal funds for fentanyl test strips, indicating a shift away from harm reduction strategies.
Astellas is moving forward with its XLMTM gene therapy trials despite earlier reports of deaths. Meanwhile, Veradermics celebrates success in its hair loss pill trial, and the FDA accelerates reviews for psychedelics.
In the podcast "Drug Story," host Thomas Goetz discusses how society often misuses medications like Ambien and Ozempic, highlighting a disconnect between drug use and bodily needs.
A recent U.S. military strike on a suspected drug boat in the Eastern Pacific resulted in six fatalities, contributing to a rising death toll linked to anti-drug operations.
Today's health news highlights the growth of an international childhood vaccine campaign alongside a shift in GOP drug policy, signaling significant changes in public health efforts.
President Trump has finalized a series of drug pricing agreements, with the last deal involving Regeneron, marking the conclusion of 17 agreements pursued by the White House.
A multiple sclerosis treatment from Sanofi has received a positive review in Europe, marking a notable shift after its rejection by the FDA last year.
Dawn Zuidegeest-Craft shares her experience of starting medical school at 69 and now preparing for residency at 72, highlighting the challenges and lessons learned.
In a notable shift from previous GOP stances, the Trump administration is now supporting research into psychedelics and reconsidering marijuana's legal status.
In a notable policy shift, President Trump has reclassified state-licensed medical marijuana as a less-dangerous drug, a change that advocates have long pursued.
Legislators in Colorado and Virginia are opposing efforts to limit the powers of prescription drug affordability boards, highlighting a significant debate over drug pricing strategies.
Federal regulators are set to unveil a new Medicare coverage pathway aimed at accelerating access to FDA-designated breakthrough medical devices, enhancing treatment options for patients.
In a recent shift, RFK Jr. has expressed support for vaccinations while also defending his previous secret agreements with pharmaceutical companies.
The Nuclear Energy Agency (NEA) recently convened a workshop to explore advancements and challenges in the supply of medical radioisotopes.
Stay informed with the latest developments in the biotech sector, featuring updates on RevMed, Roche, and Kyverna's CAR-T therapy.
Thomas Goetz emphasizes that each drug represents a broader narrative involving health, medicine, society, and economics.
Roche is advancing its experimental multiple sclerosis drug to regulators following successful trials, though significant safety concerns persist.
A judge is anticipated to impose a $225 million forfeiture on Purdue Pharma, the maker of OxyContin, facilitating the completion of its settlement with the Justice Department.
A U.S. judge is anticipated to order Purdue Pharma to forfeit $225 million, marking a significant step in ongoing legal proceedings.